cytochrome P450 family 4 subfamily A member 44, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4A44P profile across patient tissues and cancer cell-line models. CYP4A44P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CYP4A44P is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, CYP4A44P RNA expression shows 7,728 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCS, LUSC, and COAD as cancer lineages where CYP4A44P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4A44P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4A44P survival associations across molecular data types. CYP4A44P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4A44P RNA expression–survival associations across cancer types. High CYP4A44P expression shows unfavorable associations in UCS, COAD, DLBC, THCA, KIRC and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for CYP4A44P RNA expression.
This table summarizes CYP4A44P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4A44P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4A44P shows lower tumor expression in LUSC and LUAD and higher tumor expression in STAD. The LUSC box plot shows higher CYP4A44P RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p < 0.001).
This table shows molecular features associated with CYP4A44P in patient tissues and cancer cell lines. In patient samples, CYP4A44P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
